ROCHE COMUNICÓ EN FEBRERO 2024 EN EL CLINICAL TRIALS ... QUE EN EL ENSAYO DE FASE III IMFORTE YA NO RECLUTABAN PACIENTES ... HOY ROCHE COMUNICA EN EL CLINICAL TRIALS QUE EN DICHA FASE III IMFORTE ... VUELVE A RECLUTAR PACIENTES ...
A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab .
Show less .
Intervention / Treatment :
Drug: Atezolizumab
Drug: Lurbinectedin
Drug: Carboplatin
Drug: Etoposide
Other Study ID Numbers GO43104
2023-503868-16-00 ( Registry Identifier ) (REGISTRY: CTIS (EU))
Study Start (Actual) : 2021-11-18 .
Primary Completion (Estimated) : 2025-04-18 .
Study Completion ( Estimated ) : 2026-03-06 .